Trials / Active Not Recruiting
Active Not RecruitingNCT06723964
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
A Phase 1 Dose-Escalation Study to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of AP505 Injection, an Anti-PD-L1 and Anti-VEGF Bispecific Antibody, in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- AP Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors. The study will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for AP505.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AP505 | AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein. |
Timeline
- Start date
- 2023-03-30
- Primary completion
- 2024-10-31
- Completion
- 2025-11-30
- First posted
- 2024-12-09
- Last updated
- 2024-12-09
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06723964. Inclusion in this directory is not an endorsement.